Patent granted for drug candidate intended for cancer treatment

Patent granted for drug candidate intended for cancer treatment
Credit: University of Oulu / Mikko Törmänen

A potential new drug candidate developed by researchers at the University of Oulu, Finland, has been granted a patent in the United States. The drug is a small molecular chemical compound that is especially suited for cancer treatment.

The research group, led by professor Lari Lehtiö of the Faculty of Biochemistry and Molecular Medicine, found that the newly discovered compound sensitizes to DNA damage. Trials were able to show that the compound increases the effectiveness of when it is administered to cells together with cytotoxins commonly used in cancer treatment.

The compound inhibits the activity of the body's ADP-ribosyltransferase 10 (PARP10) enzyme. In our cells it has role in cellular division and repairing errors in DNA.

The patenting process for the invention started in 2015, and it is still ongoing in the United States and Europe.

The invention was created in cooperation with researchers at the University of Aachen, Germany. The researchers at the University of Oulu discovered the compound and tested the efficacy of its different versions on the activity of the PARP10 enzyme, while the researchers at the University of Aachen tested the efficacy of the compound with different cellular models.

There are many different PARP enzymes, and they are promising avenues for new cancer treatments. The first to inhibit activity of the PARP1 enzyme was introduced to the markets in 2014. The drug is used especially in the treatment of certain types of breast cancer.

The goal of the University of Oulu is to commercialize the drug candidate by licensing the to a drug development company.

Explore further

Anti-cancer drug derived from fungus shows promise in clinical trials

Provided by University of Oulu
Citation: Patent granted for drug candidate intended for cancer treatment (2021, November 8) retrieved 22 January 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors